On Thursday, JMP Securities initiated coverage on Enovis Corp (NYSE:ENOV) stock with a Market Outperform rating and a price target of $62.00. The firm highlighted the recent acquisition of LimaCorporate and the anticipated cost savings and sales synergies that have yet to be factored into the stock’s valuation.
According to the analyst from JMP Securities, the integration of LimaCorporate, which was completed at the start of the year, has brought temporary challenges to Enovis’s performance. However, these are expected to subside, and the company’s growth and earnings potential is projected to materialize in 2025 and beyond.
Despite a year-to-date decrease in stock value of approximately 25%, the analyst believes that Enovis’s current trading price does not fully reflect the benefits from the LimaCorporate acquisition or the progress made in integration efforts. The stock is currently trading at around 12 times the estimated earnings per share (EPS) for 2026.
The firm’s $62 price target for Enovis is based on applying an approximately 17 times multiple, which aligns with mid-cap growth peers, to the projected 2026 EPS of $3.60. This target suggests that Enovis is undervalued when compared to its mid-cap and orthopedic peers and should be granted a higher price-to-earnings (P/E) multiple due to upcoming top- and bottom-line growth catalysts.
In other recent news, Enovis Corporation has been making significant strides in both medical technology and financial performance. The company recently announced the successful completion of the first surgeries using its EMPOWR Revision Knee™ system with the newly integrated EMPOWR™ Cones, marking a significant advancement in Enovis’ product portfolio.
The U.S. Food and Drug Administration cleared the EMPOWR™ Cones for use earlier this year. Moreover, Enovis reported strong results for the second quarter of 2024, with a year-over-year revenue growth of 23%. The company expanded its adjusted EBITDA margins and raised its adjusted earnings per share (EPS) forecast to $2.62 to $2.77, indicating confidence in its financial outlook for the remainder of the year. These recent developments demonstrate Enovis’ commitment to innovation and financial growth.
Enovis also appointed Tim Czartoski as President of U.S. Surgical and Global Product and Enabling Technologies, bringing over two decades of experience in the medical technology field to Enovis. Lastly, Enovis is making progress in the international integration process of Lima.
InvestingPro Insights
Adding to JMP Securities’ positive outlook on Enovis Corp (NYSE:ENOV), recent data from InvestingPro provides additional context for investors. Despite the company’s current challenges, InvestingPro Tips indicate that net income is expected to grow this year, and analysts predict the company will be profitable this year. This aligns with JMP Securities’ projection of improved performance in the coming years.
However, it’s worth noting that Enovis operates with a significant debt burden and has not been profitable over the last twelve months. The stock’s price movements have been quite volatile, and it’s currently trading near its 52-week low, which could present an opportunity for investors who share JMP Securities’ optimistic view.
InvestingPro data shows that Enovis’s revenue growth remains strong, with a 17.62% increase over the last twelve months as of Q2 2024, and an even more impressive 22.56% quarterly growth in Q2 2024. The company’s gross profit margin stands at a healthy 58.8%, indicating efficient operations despite current challenges.
For investors seeking a more comprehensive analysis, InvestingPro offers 8 additional tips for Enovis, providing a deeper understanding of the company’s financial position and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
